Glycogen Synthase Kinase 3 Beta Enhances Hepatitis C Virus Replication By Supporting M R-122

Hepatitis C virus (HCV) infection is associated with alterations in host lipid and insulin signaling cascades, which are partially explained by a dependence of the HCV life cycle on key molecules in these metabolic pathways. Yet, little is known on the role in the HCV life cycle of glycogen synthase kinase 3 (GSK3), one of the most important kinases in cellular metabolism. Therefore, the impact of GSK3 on the HCV life cycle was assessed in human hepatoma cell lines harboring subgenomic genotype 1b and 2a replicons or producing cell culture-derived HCV genotype 2a by exposure to synthetic GSK3 inhibitors, GSK3 gene silencing, overexpression of GSK3 constructs and immunofluorescence analyses. In addition, the role of GSK3 in hepatitis E virus (HEV) replication was investigated to assess virus specificity of the observed findings. We found that both inhibition of GSK3 function by synthetic inhibitors as well as silencing of GSK3 beta gene expression resulted in a decrease of HCV replication and infectious particle production, whereas silencing of the GSK3 alpha isoform had no relevant effect on the HCV life cycle. Conversely, overexpression of GSK3 beta resulted in enhanced HCV replication. In contrast, GSK3 beta had no effect on replication of subgenomic HEV replicon. The pro-viral effect of GSK3 beta on HCV replication was mediated by supporting expression of microRNA-122 (miR-122), a micro-RNA which is mandatory for wild-type HCV replication, as GSK3 inhibitors suppressed miR-122 levels and as inhibitors of GSK3 had no antiviral effect on a miR-122-independent HCV mutant. In conclusion, we have identified GSK3 beta is a novel host factor supporting HCV replication by maintaining high levels of hepatic miR-122 expression.